Fungal Infection clinical trials

Explore recruiting fungal infection clinical trials.

Recruiting fungal infection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fungal Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

IMPACT – the introduction of mycotic prophylaxis at cystectomy trial. Perioperative mycotic prophylaxis to reduce postoperative complications following cystectomy – a double-blinded, placebo-controlled, randomized trial.

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Pharmacokinetics of fluconazole given orally or intravenously as prophylaxis or therapy to children and adolescents with invasive fungal infections (FOCUS)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia

Belgium, France

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 1, Multicentre, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single IV Dose of Rezafungin Acetate in Paediatric Subjects from Birth to <18 Years of Age, Receiving Systemic Antifungals as Prophylaxis for Invasive Fungal Infection or to Treat a Suspected or Confirmed Fungal Infection

Germany, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2 Years of Age With Possible, Probable, or Proven Invasive Fungal Infection

Poland, Belgium, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species

Italy, Germany, Spain, Netherlands, Belgium, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Fungal Infection trials by city

Fungal Infection in Toronto Fungal Infection in Vancouver Fungal Infection in Montreal Fungal Infection in Calgary Fungal Infection in Edmonton Fungal Infection in Ottawa Fungal Infection in Winnipeg Fungal Infection in Quebec City Fungal Infection in Hamilton Fungal Infection in Kitchener Fungal Infection in London Fungal Infection in Halifax Fungal Infection in New York Fungal Infection in Los Angeles Fungal Infection in Chicago Fungal Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease